Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

Cancer

Volumn 77, Issue 6, 1996, Pages 1144-1148

  Maulard Durdux, Catherine ^a   Dufour, Bertrand ^b   Hennequin, Christophe ^a   Chretien Y ^b   Delanian, Sylvie ^a   Housset, Martin ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

cyclophosphamide; etoposide; hormone refractory status; prostate carcinoma

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER HORMONE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SURVIVAL TIME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0029878436     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1144::AID-CNCR21>3.0.CO;2-0     Document Type: Article

References (24)

1. Klein LA. Prostatic carcinoma. N Engl J Med 1968;300:824-33.
2. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-41.
3. Henwood JM, Brogden RN. Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chemotherapy of cancer. Drugs 1990; 39:438-90.
4. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993;149:1622-5.
5. Crawford ED, Daneshgari F, Majeski SA. Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate. Semin Oncol 1992;19:53-7.
6. Pienta KJ, Redman BG, Hussain M, Esper P, Flaherty LE. Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 1995;75:1920-6.
7. Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979;44:1533-7.
8. Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn LH, and the Southwestern Cancer Study Group. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 1986;70:771-2.
9. Smart T, Hollander P, Yagoda A. Etoposide in prostatic cancer experimental studies and Phase II trials in patients with bidimensionally measurable disease. Cancer Chem Pharmacol 1986;18:24-6.
10. Slevin ML, Clark PI, Joel SP, Malik S, Osborn RJ, Gregory WM, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989;7:1333-40.
11. Hainsworth JD, Johnson DH, Frazier SR. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989;7:396-401.
12. Greco FA, Jonhson DH, Hainsworth JD. Chronic daily administration of oral etoposide. Semin Oncol 1990;17:71-4.
13. Shabel FM, Skipper HE, Trader MW, Laster WR, Griswold DP, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 1983;42:905-7.
14. Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST. In vivo resistance toward anthracyclines, etoposide and cis-diamminedichloroplatinum (II). Cancer Res 1982;42:4719-21.
15. Murphy GP, Slack NH, Mittelaman A. Experiences with estramustine phosphate in prostate cancer. Semin Oncol 1983;10(Suppl):34-45.
16. Saxman S, Ansari R, Drasga R. Phase III of cyclophosphamide versus cyclophosphamide, doxombicin, and methotrexate in hormone-refractory prostatic cancer. Cancer 1992;70:2488-92.
17. Kelly WK, Scher H, Mazumdar M, Vlamis V, Schwartz M, De Fossa S. Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 1993;11:607-15.
18. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994;74:100-3.
19. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12:2005-12.
20. Qazi R, Khandekar J. Phase II of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1983;6:203-6.
21. Rapoport BL, Falkson G. Phase II clinical study of pirarubicin in hormone-resistant prostate cancer. Invest New Drugs 1992;10:119-21.
22. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G. Suramin: a novel growth factor antagonist with activity in hormone-refractory prostate cancer. J Clin Oncol 1992;10:881-9.
23. Naito S, Ueda T, Kotoh S, Kumazawa J, Itoh K, Sagiyama K, et al. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicine and cisplatine. Cancer Chemother Pharmacol 1995;35:225-9.
24. Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M. Phase I-II study of the somatostatin analogue Lanreotide in hormone - refractory prostate cancer. Cancer Chemother Pharmacol 1995;36:259-62.